AeproMED Innovation Corp., Ltd. is building a novel inhalation therapy platform to provide chronic or illness patients with more efficient and effective inhalation therapy via advanced technology delivering personalized medicine.
Inhalation therapy offers several advantages over injection therapy, including targeted drug delivery, rapid onset of action, reduced side effects, and ease of use. We can expect to see inhalation therapy for respiratory diseases, and inhalation drugs for gene therapy and systemic disease treatment entering the market in the foreseeable future.
Future Development of Inhalation Therapy:
- Novel Drug Delivery Systems: Advances in technology have led to the development of novel drug delivery systems, such as dry powder inhalers and nebulizers, that can improve the efficacy and safety of inhaled medications.
- Personalized Medicine: Inhalation therapy has the potential to be personalized based on individual patient characteristics, such as lung function and disease severity, leading to better treatment outcomes
- Drug Formulation: Advances in drug formulation have also improved the effectiveness of inhalation therapy. The development of ultrafine particles and liposomal formulations has increased drug deposition in the lungs, which can improve therapeutic outcomes.
- Treatment of Systemic Diseases: Inhalation therapy is not limited to respiratory conditions, and there is growing interest in developing inhalation therapies for systemic diseases such as diabetes and cancer. The development of new therapies and delivery systems is expected to increase the use of inhalation therapy in the future.
